Steven A Stacker

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. ncbi Targeting lymphatic vessel functions through tyrosine kinases
    Steven P Williams
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
    J Angiogenes Res 2:13. 2010
  2. ncbi Molecular control of lymphatic metastasis
    Marc G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria 3050, Melbourne, Australia
    Ann N Y Acad Sci 1131:225-34. 2008
  3. ncbi From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy
    Steven A Stacker
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Lymphat Res Biol 6:165-72. 2008
  4. ncbi Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer
    Nicole C Harris
    Ludwig Institute for Cancer Research, Department of Surgery, The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
    FASEB J 25:2615-25. 2011
  5. ncbi A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth
    Rae H Farnsworth
    Ludwig Institute for Cancer Research, University of Melbourne, Parkville, Australia
    Cancer Res 71:6547-57. 2011
  6. ncbi A system for quantifying the patterning of the lymphatic vasculature
    Ramin Shayan
    Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Growth Factors 25:417-25. 2007
  7. ncbi Importance of Wnt signaling in the tumor stroma microenvironment
    Maria L Macheda
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
    Curr Cancer Drug Targets 8:454-65. 2008
  8. ncbi The VD1 neutralizing antibody to vascular endothelial growth factor-D: binding epitope and relationship to receptor binding
    Natalia Davydova
    Ludwig Institute for Cancer Research, Post Office Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia
    J Mol Biol 407:581-93. 2011

Collaborators

  • Marc G Achen
  • Tara Karnezis
  • Natalia Davydova
  • Steven P Williams
  • Ramin Shayan
  • Nicole C Harris
  • Rae H Farnsworth
  • Sally Roufail
  • Maria L Macheda
  • Teruhiko Sato
  • Cameron J Nowell
  • Victor A Streltsov
  • Karri Paavonen
  • You Fang Zhang
  • Masataka Matsumoto
  • Evelyn Tsantikos
  • Mark W Ashton
  • Margaret L Hibbs
  • Andrew S Runting

Detail Information

Publications8

  1. ncbi Targeting lymphatic vessel functions through tyrosine kinases
    Steven P Williams
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
    J Angiogenes Res 2:13. 2010
    ..This review will discuss the role of tyrosine kinases in lymphatic biology and the potential use of inhibitors for anti-lymphangiogenic therapy...
  2. ncbi Molecular control of lymphatic metastasis
    Marc G Achen
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria 3050, Melbourne, Australia
    Ann N Y Acad Sci 1131:225-34. 2008
    ..This article provides an overview of the molecular mechanisms that control lymphatic metastasis and discusses potential therapeutic approaches for inhibiting this process in human cancer...
  3. ncbi From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy
    Steven A Stacker
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Lymphat Res Biol 6:165-72. 2008
    ..History may show that anti-angiogenesis provided the vantage point from which anti-lymphangiogenesis was seen as a viable concept for targeting tumors and other pathological conditions...
  4. ncbi Proteolytic processing of vascular endothelial growth factor-D is essential for its capacity to promote the growth and spread of cancer
    Nicole C Harris
    Ludwig Institute for Cancer Research, Department of Surgery, The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
    FASEB J 25:2615-25. 2011
    ..Our results indicate that proteolytic processing is necessary for VEGF-D to promote the growth and spread of cancer, and suggest that enzymes catalyzing this processing could be targets for antimetastatic therapeutics...
  5. ncbi A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth
    Rae H Farnsworth
    Ludwig Institute for Cancer Research, University of Melbourne, Parkville, Australia
    Cancer Res 71:6547-57. 2011
    ..Furthermore, they implicate BMP-4 as a negative regulator of this process, suggesting its potential utility as a prognostic marker or antitumor agent...
  6. ncbi A system for quantifying the patterning of the lymphatic vasculature
    Ramin Shayan
    Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia
    Growth Factors 25:417-25. 2007
    ..This efficient, reproducible technique is validated by analysing healthy and pathological tissues...
  7. ncbi Importance of Wnt signaling in the tumor stroma microenvironment
    Maria L Macheda
    Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
    Curr Cancer Drug Targets 8:454-65. 2008
    ..Future therapeutic targets for interfering with Wnt signaling include cell surface receptors such as the RYK and Ror2 receptors and secreted signaling molecules, which mediate signaling between cancer cells and the stromal environment...
  8. ncbi The VD1 neutralizing antibody to vascular endothelial growth factor-D: binding epitope and relationship to receptor binding
    Natalia Davydova
    Ludwig Institute for Cancer Research, Post Office Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia
    J Mol Biol 407:581-93. 2011
    ....